Literature DB >> 21802815

Keratinocytes of tissue-engineered human oral mucosa promote re-epithelialization after intraoral grafting in athymic mice.

Michiko Yoshizawa1, Takahiro Koyama, Taku Kojima, Hiroko Kato, Yukiko Ono, Chikara Saito.   

Abstract

PURPOSE: The objective of this study was to investigate the role of grafted oral keratinocytes in a transplanted ex vivo-produced oral mucosa equivalent (EVPOME) in the regeneration and/or healing process of the oral mucosa at the recipient site.
MATERIALS AND METHODS: The EVPOME was developed in a serum-free defined culture system without a feeder layer. EVPOME is composed of a stratified layer of human oral keratinocytes that are seeded onto a human cadaveric dermis, AlloDerm (LifeCell, Branchburg, NJ). Intraorally grafted EVPOMEs in athymic mice (BALB/c) were excised, contiguous with the surrounding oral mucosa, on days 5, 7, 14, and 21 after grafting. Serial sections were stained with hematoxylin-eosin and immunohistochemically analyzed for cytokeratin 17 (CK17) expression to distinguish the human-cultured EVPOME epithelial keratinocytes from murine oral keratinocytes.
RESULTS: All EVPOME epithelial cells showed intense immunoreactivity for CK17, whereas mouse buccal mucosal epithelial cells did not show CK17 immunoreactivity. The grafted EVPOME maintained a stratified epithelial layer for up to 5 days after grafting. By day 7 after grafting, a portion of the EVPOME epithelial layer peeled away from the AlloDerm, and a thin, CK17-immunonegative epithelial layer extended from the adjacent thick epithelial layer of the mouse and contacted the CK17-immunopositive EVPOME epithelium. From days 14 to 21 after grafting, the stratification of the CK17-immunonegative continuous mouse epithelium increased compared with earlier time points and showed a similar appearance to the epithelium of the adjacent mouse mucosa. In contrast, no epithelial coverage of the AlloDerm that was grafted without keratinocytes was observed for up to 21 days after grafting. The grafted AlloDerm without cells resulted in tissue necrosis that was accompanied by a dramatic infiltration of inflammatory cells by day 14.
CONCLUSIONS: These findings suggest that grafting of EVPOME with viable oral keratinocytes onto an intraoral mucosal wound plays an active role in promotion of re-epithelialization of the oral wound during the subsequent healing process.
Copyright © 2012 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21802815     DOI: 10.1016/j.joms.2011.03.057

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  5 in total

Review 1.  Tissue engineering of oral mucosa: a shared concept with skin.

Authors:  Beste Kinikoglu; Odile Damour; Vasif Hasirci
Journal:  J Artif Organs       Date:  2014-10-18       Impact factor: 1.731

2.  Human oral mucosa tissue-engineered constructs monitored by Raman fiber-optic probe.

Authors:  Alexander Khmaladze; Shiuhyang Kuo; Roderick Y Kim; Robert V Matthews; Cynthia L Marcelo; Stephen E Feinberg; Michael D Morris
Journal:  Tissue Eng Part C Methods       Date:  2015-01       Impact factor: 3.056

Review 3.  The Structure and Function of Next-Generation Gingival Graft Substitutes-A Perspective on Multilayer Electrospun Constructs with Consideration of Vascularization.

Authors:  Brian C W Webb; Michael Glogauer; J Paul Santerre
Journal:  Int J Mol Sci       Date:  2022-05-09       Impact factor: 6.208

4.  Intraoral grafting of tissue-engineered human oral mucosa.

Authors:  Kenji Izumi; Rodrigo F Neiva; Stephen E Feinberg
Journal:  Int J Oral Maxillofac Implants       Date:  2013 Sep-Oct       Impact factor: 2.804

5.  Noninvasive Optical Assessment of Implanted Tissue-Engineered Construct Success In Situ.

Authors:  William R Lloyd; Seung Yup Lee; Sakib F Elahi; Leng-Chun Chen; Shiuhyang Kuo; Hyungjin Myra Kim; Cynthia Marcelo; Stephen E Feinberg; Mary-Ann Mycek
Journal:  Tissue Eng Part C Methods       Date:  2021-05       Impact factor: 3.056

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.